Telix Pharmaceuticals

Telix Pharmaceuticals

World Rank (Jan-05-2024)
5,516
Market Cap (Jan-05-2024)
2.097 Billion USD
World Rank (Jul-30-2023)
5,121
Market Cap (Jul-30-2023)
2.385 Billion USD
World Rank (Jan-07-2022)
6,854
Market Cap (Jan-07-2022)
1.735 Billion USD
World Rank (Jan-01-2021)
8,819
Market Cap (Jan-01-2021)
0.815 Billion USD
Company Rank in Country in 2023
Rank in Australia in July-2023 is 104
Headquarters Country
Australia
World Region
Oceania
World Subregion
Australia and New Zealand
Annual Revenue in USD
5 Million USD
Annual Net Income in USD
-59 Million USD
Annual Results for Period Ending
Dec-2021 ending year
Total Assets in USD
81 Million USD
Total Liabilities in USD
79 Million USD
Total Equity in USD
1 Million USD
Balance Sheet for Period Ending
Dec-2021 ending year
Business Sector
Healthcare
Pharmaceutical
HealthCare Products
Biotechnology
Company Website
TELIX PHARMACEUTICALS
Yahoo
Yahoo @ ASX
Company Profile
Telix Pharmaceuticals is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic (‘theranostic’) assets using Molecularly Targeted Radiation (MTR). The company annual revenue is 7 million AUD as on 2021. The headquarters is in Australia.
Founded Year
2015
Stock Exchange
ASX
Company SubCategory
Top Healthcare Companies in Australia

Share